Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Antiviral Agents; Ribavirin; Sofosbuvir

Criteria

Inclusion Criteria:

• All transplanted patients for HCV related disease in the period from 2014 to 2016

Exclusion Criteria:

• Patients transplanted for other causes rather than HCv

• Patients with HBV and HCV co infection